Pfizer Expands mRNA Technology Access Through Acuitas Therapeutics Agreement
Pfizer Inc. has entered into a development and option agreement with Acuitas Therapeutics to access its lipid nanoparticle (LNP) delivery system technology. The agreement grants Pfizer the option to license Acuitas' LNP technology for up to 10 targets for vaccine or therapeutic development.
NEW YORK & VANCOUVER, British Columbia – Pfizer Inc. has entered into a development and option agreement with Acuitas Therapeutics, a company focused on developing lipid nanoparticle (LNP) delivery systems for messenger RNA (mRNA) therapeutics. The agreement provides Pfizer with the option to license, on a non-exclusive basis, Acuitas' LNP technology for up to 10 targets for vaccine or therapeutic development.
Acuitas' clinically validated LNP technology is already in use in COMIRNATY®, the Pfizer-BioNTech COVID-19 vaccine. This collaboration strategically enhances Pfizer's existing mRNA platform.
Mikael Dolsten, M.D., Ph.D., Chief Scientific Officer and President, Worldwide Research, Development and Medical of Pfizer, stated that the agreement expands Pfizer's LNP capabilities and allows for exploration of more projects within existing vaccine areas and new therapeutic fields where mRNA-LNP technology holds potential.
Dr. Thomas Madden, President & CEO of Acuitas Therapeutics, expressed pride in their LNP technology's contribution to COMIRNATY® and enthusiasm for advancing new vaccines and therapeutics with Pfizer.